Irach Taraporewala

Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY.

Mystic Pharmaceuticals, Inc. manufactures and wholesales pharmaceutical and biological products. The private company was founded in 2003 and is based in Austin, TX.

ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ.

Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY.

DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY.

Part of EOM Pharmaceuticals Holdings, Inc., EOM Pharmaceuticals, Inc. is a privately held, clinical-stage company focused on developing novel drugs to improve the quality of life for patients with debilitating and sometimes deadly diseases. The company is based in Montvale, NJ. The company's mission is to pursue innovative approaches with small molecule therapeutics to address urgent and unmet medical needs. EOM's pipeline includes the development of the first-and-only dual-acting, broad-spectrum immunomodulator EOM613, which has the potential to treat systemic illnesses caused by intense inflammatory immune reactions, including COVID-19, influenza, and cancer cachexia. Additionally, EOM is working on an advanced formulation of EOM147, the first potential topically administered eye drop for treating retinal diseases. The company was founded by Shalom Z. Hirschman and Eli Goldberger, and Irach B. Taraporewala has been the CEO since 2020. EOM Pharmaceuticals was acquired by ImmunoCellular Therapeutics Ltd. on December 02, 2021.